Fox Run Management’s Ascendis Pharma A/S ASND Stock Holding History

Fox Run Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.26M	Buy	+4,726	New	+$1.1M	0.21%	108
2026 Q1	–	Sell	-4,496	Closed	-$959K	–	903
2025 Q4	$959K	Buy	4,496 +2,830	+170%	+$584K	0.15%	227
2025 Q3	$331K	Buy	+1,666	New	+$311K	0.05%	653
2024 Q3	–	Sell	-3,613	Closed	-$493K	–	792
2024 Q2	$493K	Buy	+3,613	New	+$492K	0.09%	415
2024 Q1	–	Sell	-2,986	Closed	-$376K	–	746
2023 Q4	$376K	Buy	+2,986	New	+$298K	0.1%	417
2023 Q2	–	Sell	-4,427	Closed	-$475K	–	679
2023 Q1	$475K	Buy	+4,427	New	+$506K	0.15%	234

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Fox Run Management's ASND Position: Q2 2026 in Review

Fox Run Management opened a new position in Ascendis Pharma A/S (ASND) in Q2 2026: 4,726 shares worth $1.26M. The stake represents 0.21% of the portfolio and ranks #108 among its holdings. This is a return to the name: Fox Run Management previously reported a position in ASND as recently as Q4 2025.

Fox Run Management first reported a position in ASND in Q1 2023 and has held it in 6 quarters since. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Fox Run Management held 4,726 shares of Ascendis Pharma A/S worth $1.26M as of Q2 2026.
Ascendis Pharma A/S was a new Fox Run Management position in Q2 2026.
Ascendis Pharma A/S made up 0.21% of Fox Run Management's portfolio in Q2 2026, its #108 holding.
Fox Run Management first reported a position in Ascendis Pharma A/S in Q1 2023 and has held it in 6 quarters since.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.